VTYX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Ventyx Biosciences's net margin of --. Ventyx Biosciences's return on equity of -- beat CEL-SCI's return on equity of --.

Ventyx Biosciences has a consensus price target of $11.14, signalling upside risk potential of 378.23%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 997.08%. Given that CEL-SCI has higher upside potential than Ventyx Biosciences, analysts believe CEL-SCI is more attractive than Ventyx Biosciences.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Ventyx Biosciences's net income of -$35.2M is lower than CEL-SCI's net income of -$6.9M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Ventyx Biosciences's net margin of -416.75%. Ventyx Biosciences's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Ventyx Biosciences has a consensus price target of $11.14, signalling upside risk potential of 378.23%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 919.02%. Given that IGC Pharma has higher upside potential than Ventyx Biosciences, analysts believe IGC Pharma is more attractive than Ventyx Biosciences.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Ventyx Biosciences's net income of -$35.2M is lower than IGC Pharma's net income of -$1.7M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus 21.53x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Neurogene has a net margin of -- compared to Ventyx Biosciences's net margin of -1999.14%. Ventyx Biosciences's return on equity of -- beat Neurogene's return on equity of --.

Ventyx Biosciences has a consensus price target of $11.14, signalling upside risk potential of 378.23%. On the other hand Neurogene has an analysts' consensus of $52.80 which suggests that it could grow by 119.09%. Given that Ventyx Biosciences has higher upside potential than Neurogene, analysts believe Ventyx Biosciences is more attractive than Neurogene.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neurogene has a beta of 1.235, suggesting its more volatile than the S&P 500 by 23.528%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurogene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Neurogene pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than Neurogene quarterly revenues of $925K. Ventyx Biosciences's net income of -$35.2M is lower than Neurogene's net income of -$20.2M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Neurogene's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus -- for Neurogene. Usually stocks with elevated PS ratios are considered overvalued.

Regulus Therapeutics has a net margin of -- compared to Ventyx Biosciences's net margin of --. Ventyx Biosciences's return on equity of -- beat Regulus Therapeutics's return on equity of --.

Ventyx Biosciences has a consensus price target of $11.14, signalling upside risk potential of 378.23%. On the other hand Regulus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 545.83%. Given that Regulus Therapeutics has higher upside potential than Ventyx Biosciences, analysts believe Regulus Therapeutics is more attractive than Ventyx Biosciences.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regulus Therapeutics has a beta of 1.612, suggesting its more volatile than the S&P 500 by 61.188%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regulus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Regulus Therapeutics pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than Regulus Therapeutics quarterly revenues of --. Ventyx Biosciences's net income of -$35.2M is lower than Regulus Therapeutics's net income of -$14.1M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Regulus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus -- for Regulus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.